中国合理用药探索2025，Vol.22Issue(6)：13-18,6.DOI:10.3969/j.issn.2096-3327.2025.06.003
特瑞普利单抗联合新辅助化疗对高龄食管癌患者免疫功能及血管内皮生长因子水平的影响
Influence of Toripalimab Combined with Neoadjuvant Chemotherapy on Immune Function and Vascular Endothelial Growth Factor in Elderly Patients with Esophageal Cancer
摘要
Abstract
Objective:To investigate the clinical efficacy of toripalimab combined with neoadjuvant chemotherapy in elderly patients with esophageal cancer,and analyze its impact on immune function and serum vascular endothelial growth factor(VEGF).Methods:A total of 196 elderly patients with esophageal cancer admitted to our hospital from October 2019 to December 2023 were randomly divided into the control group(neoadjuvant chemotherapy)and observation group(toripalimab+neoadjuvant chemotherapy)using a random number table,with 98 cases in each group.Changes in tumor related factors,immune indices,and adverse reactions were observed after treatment.Results:The observation group showed significantly higher tumor reduction rate and complete resection rate(both P＜0.05),and lower 1-year recurrence rate(P＜0.05)compared with the control group.Levels of carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCC-Ag),tumor related factors were lower(P＜0.05),while VEGF,CD4+,and CD4+/CD8+ratios were higher(P＜0.05)in the observation group.Multivariate linear regression indicated that complete resection and toripalimab combined with preoperative neoadjuvant chemotherapy were associated with changes in PD-1,CD4+,and CD4+/CD8+levels(P＜0.05).No significant difference in adverse reaction incidence was found between groups(P＞0.05).Conclusion:Toripalimab combined with neoadjuvant chemotherapy effectively inhibits,tumor related factors,promotes tumor shrinkage and complete resection,enhances immune function,and reduces local recurrence in elderly esophageal cancer patients.关键词
食管癌/新辅助化疗/特瑞普利单抗/免疫功能/血管内皮生长因子Key words
esophageal cancer/neoadjuvant chemotherapy/toripalimab/immune function/vascular endothelial growth factor分类
医药卫生引用本文复制引用
李浩淼,巴玉峰,吕宏伟,朱建平,于永魁,邢文群..特瑞普利单抗联合新辅助化疗对高龄食管癌患者免疫功能及血管内皮生长因子水平的影响[J].中国合理用药探索,2025,22(6):13-18,6.基金项目
2023年河南省医学科技攻关计划项目(LHGJ20230103) （LHGJ20230103）
